Adoption of Lutetium-
Health services research
Lutetium-177 PSMA (177Lu-PSMA)
Prostate cancer
Radioligand therapy
Trends
mCRPC
Journal
European journal of nuclear medicine and molecular imaging
ISSN: 1619-7089
Titre abrégé: Eur J Nucl Med Mol Imaging
Pays: Germany
ID NLM: 101140988
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
received:
19
12
2022
accepted:
07
02
2023
medline:
22
5
2023
pubmed:
25
2
2023
entrez:
24
2
2023
Statut:
ppublish
Résumé
This study is to investigate the adoption and current trends of Lutetium- We analyzed data from the reimbursement.INFO tool based on German hospitals' quality reports for Lutetium- General therapy with open radionuclides increased from 2006 to 2020. We identified a total of 12,553 Treatment of mCRPC with
Identifiants
pubmed: 36826478
doi: 10.1007/s00259-023-06139-x
pii: 10.1007/s00259-023-06139-x
pmc: PMC10199877
doi:
Substances chimiques
Prostate-Specific Antigen
EC 3.4.21.77
Lutetium
5H0DOZ21UJ
Radioisotopes
0
Heterocyclic Compounds, 1-Ring
0
Dipeptides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2188-2195Informations de copyright
© 2023. The Author(s).
Références
Marques RB, Dits NF, Erkens-Schulze S, et al. Bypass mechanisms of the androgen receptor pathway in therapy-resistant prostate cancer cell models. PLoS ONE. 2010;5(10): e13500.
doi: 10.1371/journal.pone.0013500
pubmed: 20976069
pmcid: 2957443
Farolfi A, Fendler W, Iravani A, et al. Theranostics for advanced prostate cancer: current indications and future developments. Eur Urol Oncol. 2019;2(2):152–62. https://doi.org/10.1016/j.euo.2019.01.001 .
doi: 10.1016/j.euo.2019.01.001
pubmed: 31017091
Gadot M, Davidson T, Aharon M, et al. Clinical variables associated with PSA response to Lutetium-177-PSMA ([177Lu]-PSMA-617) radionuclide treatment in men with metastatic castration-resistant prostate cancer. Cancers (Basel). 2020;12(5):1078. Published 2020 Apr 26. https://doi.org/10.3390/cancers12051078 .
Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12):1091–103. https://doi.org/10.1056/NEJMoa2107322 .
doi: 10.1056/NEJMoa2107322
pubmed: 34161051
pmcid: 8446332
Cornford P, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG Guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71(4):630–42. https://doi.org/10.1016/j.eururo.2016.08.002 .
doi: 10.1016/j.eururo.2016.08.002
pubmed: 27591931
Emmett L, Willowson K, Violet J, Shin J, Blanksby A, Lee J. Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy. J Med Radiat Sci. 2017;64(1):52–60. https://doi.org/10.1002/jmrs.227 .
doi: 10.1002/jmrs.227
pubmed: 28303694
pmcid: 5355374
Meyrick D, Gallyamov M, Sabarimurugan S, Falzone N, Lenzo N. Real-world data analysis of efficacy and survival after Lutetium-177 labelled PSMA ligand therapy in metastatic castration-resistant prostate cancer. Target Oncol. 2021;16(3):369–80.
doi: 10.1007/s11523-021-00801-w
pubmed: 33687624
Rahbar K, Ahmadzadehfar H, Kratochwil C, et al. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2017;58(1):85–90. https://doi.org/10.2967/jnumed.116.183194 .
doi: 10.2967/jnumed.116.183194
pubmed: 27765862
Calopedos RJS, et al. Lutetium-177-labelled anti-prostate-specific membrane antigen antibody and ligands for the treatment of metastatic castrate-resistant prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2017;20:352.
doi: 10.1038/pcan.2017.23
pubmed: 28440324
Benešová M, Schafer M, Bauder-Wust U, et al. Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med. 2015;56:914–20.
doi: 10.2967/jnumed.114.147413
pubmed: 25883127
Eiber M, Heck M, Tauber R, et al. Systemic radioligand therapy with 177Lu-PSMA I&T in patients with metastatic castration-resistant prostate cancer. J Nucl Med. 2016;57(supplement 2):61–61.
Ghosh A, Heston WD. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004;91(3):528–39. https://doi.org/10.1002/jcb.10661 .
doi: 10.1002/jcb.10661
pubmed: 14755683
Tagawa ST, Milowsky MI, Morris M, Vallabhajosula S, Christos P, Akhtar NH, et al. Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013;19(18):5182–91. https://doi.org/10.1158/1078-0432.CCR-13-0231 .
doi: 10.1158/1078-0432.CCR-13-0231
pubmed: 23714732
pmcid: 3778101
Seitzer KE, Seifert R, Kessel K, et al. Lutetium-177 labelled PSMA targeted therapy in advanced prostate cancer: current status and future perspectives. Cancers (Basel). 2021;13(15):3715. Published 2021 Jul 23. https://doi.org/10.3390/cancers13153715 .
Weber M, Hadaschik B, Ferdinandus J, et al. Prostate-specific membrane antigen-based imaging of castration-resistant prostate cancer. Eur Urol Focus. 2021;7(2):279–87. https://doi.org/10.1016/j.euf.2021.01.002 .
doi: 10.1016/j.euf.2021.01.002
pubmed: 33483289
Seifert R, Alberts IL, Afshar-Oromieh A, Rahbar K. Prostate cancer theranostics: PSMA targeted therapy. PET Clin. 2021;16(3):391–6. https://doi.org/10.1016/j.cpet.2021.03.004 .
doi: 10.1016/j.cpet.2021.03.004
pubmed: 34053583
Flegar L, Kraywinkel K, Zacharis A, Aksoy C, Koch R, Eisenmenger N, Groeben C, Huber J. Treatment trends for muscle-invasive bladder cancer in Germany from 2006 to 2019. World J Urol. 2022;40(7):1715–21. https://doi.org/10.1007/s00345-022-04017-z .
doi: 10.1007/s00345-022-04017-z
pubmed: 35486177
pmcid: 9237006
Flegar L, Zacharis A, Aksoy C, Heers H, Derigs M, Eisenmenger N, Borkowetz A, Groeben C, Huber J. Alternative- and focal therapy trends for prostate cancer: a total population analysis of in-patient treatments in Germany from 2006 to 2019. World J Urol. 2022;40(7):1645–52. https://doi.org/10.1007/s00345-022-04024-0 .
doi: 10.1007/s00345-022-04024-0
pubmed: 35562598
pmcid: 9236973
Benchimol EI, Smeeth L, Guttmann A, Harron K, Moher D, Petersen I, et al. The reporting of studies conducted using observational routinely-collected health data (RECORD) statement. PLoS Med. 2015;12(10):e1001885. https://doi.org/10.1371/journal.pmed.1001885 .
Ahmadzadehfar H, Albers P, Bockisch A, et al. Lutetium-177-PSMA-Radioligandentherapie. Urologe. 2018;57:709–13. https://doi.org/10.1007/s00120-018-0642-2 .
doi: 10.1007/s00120-018-0642-2
Hope TA. From compassionate use to phase 3 trial: the impact of Germany’s PSMA-617 literature. J Nucl Med. 2020;61(Suppl 2):255S-256S. https://doi.org/10.2967/jnumed.120.252122 .
doi: 10.2967/jnumed.120.252122
pubmed: 33293446
Groener D, Nguyen CT, Baumgarten J, et al. Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer. EJNMMI Res. 2021;11(1):61. Published 2021 Jul 3. https://doi.org/10.1186/s13550-021-00805-7 .
Huber J, Brogsitter C, Kotzerke J et al. Prostatakarzinom: palliative Therapie. In: Michel, M., Thüroff, J., Janetschek, G., Wirth, M. (eds) Die urologie. Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-41168-7_144-1 .
Agrawal S. The role of 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: Is it the new beginning. Indian J Urol. 2020;36(1):69–70. https://doi.org/10.4103/iju.IJU_266_19 .
doi: 10.4103/iju.IJU_266_19
pubmed: 31983833
pmcid: 6961440
Heck MM, Tauber R, Schwaiger S, et al. Treatment outcome, toxicity, and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer. Eur Urol. 2019;75(6):920–6. https://doi.org/10.1016/j.eururo.2018.11.016 .
doi: 10.1016/j.eururo.2018.11.016
pubmed: 30473431
Plichta KA, Graves SA, Buatti JM. Prostate-specific membrane antigen (PSMA) theranostics for treatment of oligometastatic prostate cancer. Int J Mol Sci. 2021;22(22):12095. Published 2021 Nov 9. https://doi.org/10.3390/ijms222212095 .
Privé BM, Peters SMB, Muselaers CHJ, et al. Lutetium-177-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer: a prospective pilot study. Clin Cancer Res. 2021;27(13):3595–601. https://doi.org/10.1158/1078-0432.CCR-20-4298 .
doi: 10.1158/1078-0432.CCR-20-4298
pubmed: 33883176
Privé BM, Muselaers CHJ, van Oort IM, Janssen MJR, Peters SMB, van Gemert WAM, Uijen MJM, Schilham MMG, Sedelaar JPM, Westdorp H, Mehra N, Gotthardt M, Barentsz JO, Gerritsen WR, Witjes JA, Nagarajah J. An update to the pilot study of 177Lu-PSMA in low volume hormone-sensitive prostate cancer. Front Nucl Med. 2022;2:863101. https://doi.org/10.3389/fnume.2022.863101 .
doi: 10.3389/fnume.2022.863101
Ahmadzadehfar H, Rahbar K, Baum RP, et al. Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial). Eur J Nucl Med Mol Imaging. 2021;48(1):113–22. https://doi.org/10.1007/s00259-020-04797-9 .
doi: 10.1007/s00259-020-04797-9
pubmed: 32383093